AbbVie Inc. (ABBV) Capital Expenditures
The capex for AbbVie Inc. (ABBV) is $1.21 Billion with a year-over-year change of +24.64%. Capital Expenditures (CapEx) represents spending on physical assets like property, plant, equipment, and technology infrastructure. It's the investment in the company's future productive capacity.
ABBV CapEx Chart
Current CapEx
$1.21B
$1.21 Billion
Year-over-Year Change
+24.64%
vs. $974.00M prior year
Historical Data
17
Years of data available
Annual CapEx History
| Year | CapEx | YoY Change | % Change |
|---|---|---|---|
| 2025 | $1.21B | +$240.00M | +24.64% |
| 2024 | $974.00M | +$197.00M | +25.35% |
| 2023 | $777.00M | +$82.00M | +11.80% |
| 2022 | $695.00M | $-92.00M | -11.69% |
| 2021 | $787.00M | $-11.00M | -1.38% |
| 2020 | $798.00M | +$246.00M | +44.57% |
| 2019 | $552.00M | $-86.00M | -13.48% |
| 2018 | $638.00M | +$109.00M | +20.60% |
| 2017 | $529.00M | +$50.00M | +10.44% |
| 2016 | $479.00M | $-53.00M | -9.96% |
| 2015 | $532.00M | $-80.00M | -13.07% |
| 2014 | $612.00M | +$121.00M | +24.64% |
| 2013 | $491.00M | +$158.00M | +47.45% |
| 2012 | $333.00M | $-22.52M | -6.33% |
| 2011 | $355.51M | $-92.48M | -20.64% |
| 2010 | $448.00M | +$135.44M | +43.33% |
| 2009 | $312.56M | — | — |
About AbbVie Inc.
AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active rheumatoid arthritis in adult patients. Oncology and Hematology: For blood cancers, AbbVie provides IMBRUVICA and VENCLEXTA (a BCL-2 inhibitor), both indicated for adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Virology: MAVYRET offers a treatment option for individuals with chronic HCV genotype 1-6 infection. Gastroenterology and Endocrinology: The company supplies CREON, an enzyme replacement therapy for exocrine pancreatic insufficiency, and Synthroid, used to manage hypothyroidism. Linzess/Constella helps treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation. Women's Health and Urology: Lupron serves as a palliative treatment for conditions like advanced prostate cancer, endometriosis, central precocious puberty, and anemia caused by uterine fibroids. ORILISSA, a nonpeptide small molecule GnRH antagonist, is designed for women experiencing moderate to severe endometriosis pain. Neurology: AbbVie offers Duopa and Duodopa, a levodopa-carbidopa intestinal gel for Parkinson's disease, and Ubrelvy to treat migraines (with or without aura) in adults. The therapeutic formulation of Botox is also part of its offerings. Ophthalmology: Its eye care segment features Lumigan/Ganfort (a bimatoprost ophthalmic solution) and Alphagan/Combigan (an alpha-adrenergic receptor agonist), both aimed at reducing elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension. Restasis, a calcineurin inhibitor immunosuppressant, is provided to enhance tear production, alongside other specialized eye care products. AbbVie Inc. also engages in research collaborations, including a partnership with Dragonfly Therapeutics, Inc. The company was founded in 2012 and operates from its headquarters in North Chicago, Illinois.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Robert A. Michael